Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsRecruiting
NCT07468071Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer · Advanced Solid Tumors Harboring the KRAS G12C Mutation
Belgium, Canada, China, Denmark, France +4 more
Dabrafenib and/or Trametinib Rollover StudyRecruiting
NCT03340506Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Melanoma · Non Small Cell Lung Cancer · Solid Tumor · Rare Cancers
United States, Argentina, Austria, China, Denmark +7 more
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruiting
NCT07491445Phase 3Updated Aug 18, 2026
Sponsor: Revolution Medicines, Inc.
Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma
United States, Australia, Japan
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruiting
NCT07415031Phase 2Updated Aug 18, 2026
Sponsor: Mirati Therapeutics Inc.
Solid Tumors
United States, Australia, Belgium, Canada, China +15 more
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerActive Not Recruiting
NCT03732820Phase 3Updated Aug 18, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
United States, Australia, Belgium, Brazil, Canada +12 more
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1Recruiting
NCT07486934Phase 3Updated Aug 18, 2026
Sponsor: Dyne Therapeutics
Myotonic Dystrophy Type 1 (DM1) · DM1 · Myotonic Dystrophy · Steinert Disease
United States, Belgium, Denmark, France, Germany +5 more
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Recruiting
NCT03486873Phase 3Updated Aug 18, 2026
Sponsor: Merck Sharp & Dohme LLC
Solid Tumors · Hematologic Malignancies
United States, Argentina, Australia, Austria, Belgium +46 more
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)Terminated
NCT05665595Phase 3Updated Aug 18, 2026
Sponsor: Merck Sharp & Dohme LLC
Melanoma
United States, Argentina, Australia, Austria, Belgium +21 more
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisRecruiting
NCT07201922Phase 3Updated Aug 18, 2026
Sponsor: Boehringer Ingelheim
Familial Pulmonary Fibrosis · Interstitial Lung Abnormalities · Interstitial Lung Diseases
United States, Argentina, Australia, Belgium, Canada +8 more
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6Terminated
NCT06091930Phase 1Updated Aug 18, 2026
Sponsor: Boehringer Ingelheim
Gastrointestinal Cancer · Lung Cancer · Pancreatic Cancer · Colorectal Cancer
Japan
A Study of Obexelimab in Patients With Systemic Lupus ErythematosusActive Not Recruiting
NCT06559163Phase 2Updated Aug 18, 2026
Sponsor: Zenas BioPharma (USA), LLC
Systemic Lupus Erythematosus
United States, Belgium, Bulgaria, Canada, China +13 more
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)Active Not Recruiting
NCT05156281Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
United States, Argentina, Brazil, Bulgaria, Canada +22 more
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast CancerRecruiting
NCT06888388N/AUpdated Aug 18, 2026
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Breast Cancer Surgery
United States, Australia, Belgium, Canada, Japan +3 more
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver CancerRecruiting
NCT06764316Phase 1Updated Aug 18, 2026
Sponsor: Bayer
Hepatocellular Carcinoma
United States, Belgium, Canada, China, Finland +4 more
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerRecruiting
NCT06764485Phase 3Updated Aug 18, 2026
Sponsor: Celgene
Metastatic Castration-resistant Prostate Cancer
United States, Argentina, Australia, Austria, Brazil +21 more
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung CancerRecruiting
NCT07325136Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Bristol-Myers Squibb
Relapsed/Refractory Small Cell Lung Cancer
United States, China, Italy, Japan, Romania +1 more
A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese AdultsRecruiting
NCT07612813Phase 1Updated Aug 18, 2026
Sponsor: AstraZeneca
Staphylococcus Aureus Bloodstream Infection
Japan
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Recruiting
NCT07291076Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Bristol-Myers Squibb
Hepatocellular Carcinoma (HCC)
United States, Australia, Chile, China, France +9 more
Secukinumab Open Label Roll-over Extension ProtocolRecruiting
NCT04638647Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Autoimmunity, Inflammation
United States, Brazil, Bulgaria, China, Colombia +15 more
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruiting
NCT04772079Phase 3Updated Aug 18, 2026
Sponsor: Bristol-Myers Squibb
Plaque Psoriasis
Argentina, Australia, Brazil, Canada, France +8 more
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)Recruiting
NCT06615479Phase 3Updated Aug 18, 2026
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Relapsed or Refractory Multiple Myeloma (RRMM)
United States, Argentina, Australia, Austria, Belgium +26 more
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia AreataRecruiting
NCT07617597Phase 3Updated Aug 18, 2026
Sponsor: Sun Pharma Japan Limited
Alopecia Areata
Japan
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCRecruiting
NCT07226986Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
United States, Australia, France, Germany, Italy +2 more
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)Recruiting
NCT07405151Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Merck Sharp & Dohme LLC
Oesophageal Squamous Cell Carcinoma
United States, Brazil, China, Czechia, Japan +5 more
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasRecruiting
NCT06090539Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Bristol-Myers Squibb
Relapsed/Refractory Non-Hodgkin Lymphoma
United States, Chile, China, France, Germany +10 more

Previous page Next page